Economic Analysis of Batch and Continuous Biopharmaceutical Antibody Production: a Review

Abstract

Purpose: There is a growing interest in continuous biopharmaceutical processing due to the advantages of small footprint, increased productivity, consistent product quality, high process flexibility and robustness, facility cost-effectiveness, and reduced capital and operating cost. To support the decision making of biopharmaceutical manufacturing, comparisons between conventional batch and continuous processing are provided. Methods: Various process unit operations in different operating modes are summarized. Software implementation, as well as computational methods used, are analyzed pointing to the advantages and disadvantages that have been highlighted in the literature. Economic analysis methods and their applications in different parts of the processes are also discussed with examples from publications in the last decade. Results: The results of the comparison between batch and continuous process operation alternatives are discussed. Possible improvements in process design and analysis are recommended. The methods used here do not reflect Lilly's cost structures or economic evaluation methods. Conclusion: This paper provides a review of the work that has been published in the literature on computational process design and economic analysis methods on continuous biopharmaceutical antibody production and its comparison with a conventional batch process.

Implementation of Stir-Speed Adopted Controllers Onto a Batch Bioreactor for Improved Fermentation

“…The article points out that the advantage of batch bioreactors is mainly their undemanding use, the advantage of fed-batch bioreactors is cost-effective operation (but they require complex handling and poses more challenges for operators), and continuous bioreactors enable operation in a state where the growth rate is purely controlled feeding rate, which is very useful for control in both academic rate and industrial production. In [9], a review of an economic analysis of batch and continuous biopharmaceutical production is carried out. The analysis particularly brought up that lack of automation still exists.…”

The Current Status, Trend, and Development Strategies of Chinese Biopharmaceutical Industry With a Challenging Perspective

“…Under the guidance and promotion of Chinese national policies, research centers of biopharmaceutical technology have been established in various regions of China (Eissa, 2017;Farid, 2019;Langer & Rader, 2017;Liu & Li, 2016;Yan, 2014;Yang et al, 2019;Zhou & Li, 2013). For example, in 1993, China established the Bioengineering Society and Shenzhen Kexing Biological Products Inc., the largest genetic engineering manufacturer in China.…”

“…Chinese "Eleventh Five-Year Plan," "Twelfth Five-Year Plan," and "Thirteenth Five-Year Plan" all regard the biological industry as the key development direction. For example, in December 2016, the State Council issued the "13th Five-Year National Strategic Emerging Industry Development Plan," proposing to accelerate the cultivation and development of five pillar industries with an annual output value of 10 trillion Yuan, and established the bio-industry as the key position in the future development of the national economy (Eissa, 2017;Farid, 2019;Yang et al, 2019). The "Plan" proposes that by 2020, the scale of the bio-industry will reach 8 to 10 trillion Yuan.…”

Curriculum design for training applied students of biopharmaceutical engineering based on the product life cycle

“…The global sales of monoclonal antibodies quickly increased from $39 billion to $75 billion from the year 2008 to 2013. Under this rate of increase, the global sales of monoclonal antibodies are expected to reach $125 billion by 2020 and $139 billion by 2024 [24].…”